Michael F. Drummond Boeken

Since its release in 1987, this book has established itself as the leading textbook in the field of economic evaluation in health care. The past decade has seen significant growth in this area, marked by an increase in published studies and a greater acknowledgment of their role in health care decision-making. Recent advancements have also led to the development of various methodological guidelines, including those from the United States Public Health Services Panel. The new edition retains the original's structure while introducing a critical appraisal checklist applicable to any study. It delves deeper into the main forms of analysis: cost analysis, cost-effectiveness analysis, cost-utility analysis, and cost-benefit analysis. This revised edition has expanded significantly, particularly in the areas of cost-utility and cost-benefit analysis, reflecting major methodological advancements. New chapters focus on data collection, analysis, and the presentation and utilization of economic evaluation results. This edition is essential for anyone involved in commissioning, conducting, or applying economic evaluations in health care, appealing to health service professionals, economists, and decision-makers alike. Reviews of the first edition highlight its importance and comprehensive coverage, affirming its status as a crucial resource in the field.

The story of how three software engineers at Microsoft developed DirectX and Chromeffects.

This book provides a detailed review of the role of health technology assessment (HTA) in the European Union. It examines both method and process in the prioritization and financing of modern health care and presents extensive case studies from Sweden, the Netherlands, Finland, France, Germany and the United Kingdom.The book examines a number of issues, with particular emphasis on the responsibility and membership of HTA bodies’ assessment procedures and methods, the application of HTA evidence to decision-making, and the dissemination and implementation of findings. It aims to highlight ways to improve the HTA process in Europe by examining key challenges and identifying opportunities to support value and innovation in health care.It will be vital reading for a wide range of stakeholders including policy-makers, HTA bodies, manufacturers, health-care professionals and patient organizations.